Williams J G, De Voss K, Craswell P W
Med J Aust. 1978 Feb 25;1(4):225-8. doi: 10.5694/j.1326-5377.1978.tb107854.x.
The efficacy of labetalol in lowering blood pressure was assessed in 18 patients with chronic renal failure and hypertension. Before the start of labetalol therapy, all patients were receiving combined antihypertensive therapy, the most common being a beta-blocker and hydrallazine. Over the period of about four weeks labetalol was substituted for the prior therapy. 51Cr edetic acid (EDTA) estimations of glomerular filtration rate were performed before labetalol therapy, and then again after one and six months. Before the therapy with labetalol, 12 of the 18 patients had supine diastolic blood pressures of 100 mm Hg or more. At six months, 14 patients remained in the trial and, of these, only four had a supine diastolic blood pressure of 100 mm Hg or more. In the supine position there was a significant reduction of systolic, but not of diastolic, blood pressure. However, in the erect position there was a significant reduction both in systolic and in diastolic blood presure. Pulse rate did not vary significantly. Few side effects were encountered, transient postural dizziness being the most common side effect. Labetalol seems to be an effective substitute for the beta-blocker plus hydrallazine therapy. However, it is not as potent as minoxidil.
在18例慢性肾衰竭合并高血压患者中评估了拉贝洛尔的降压疗效。在开始拉贝洛尔治疗前，所有患者均接受联合降压治疗，最常用的是β受体阻滞剂和肼屈嗪。在约四周的时间里，用拉贝洛尔替代了先前的治疗。在拉贝洛尔治疗前、治疗1个月和6个月后分别进行了51铬依地酸（EDTA）肾小球滤过率测定。在拉贝洛尔治疗前，18例患者中有12例仰卧位舒张压≥100 mmHg。6个月时，14例患者仍在试验中，其中只有4例仰卧位舒张压≥100 mmHg。仰卧位时收缩压显著降低，但舒张压未降低。然而，站立位时收缩压和舒张压均显著降低。脉搏率无显著变化。很少出现副作用，最常见的副作用是短暂性体位性头晕。拉贝洛尔似乎是β受体阻滞剂加肼屈嗪治疗的有效替代药物。然而，它不如米诺地尔有效。
